Lilly, Boehringer advance biosimilar diabetes drug in Europe; Novartis partners on new vaccines

 @FierceBiotech: SEC hunting down traders who made a quick killing on Onyx shares. Report | Follow @FierceBiotech

 @JohnCFierce: Top Novartis blockbuster prospect whips Enbrel in psoriasis showdown. News | Follow @JohnCFierce

 @RyanMFierce: For those of you who remember Son of Lantus, watch out for Lantus' fraternal (not identical) twin from Lilly and Boehringer. | Follow @RyanMFierce

 @EmilyMFierce: Cholera is altering the human genome. Story | Follow @EmilyMFierce

> Eli Lilly ($LLY) and Boehringer Ingelheim announced that their marketing authorization application for LY2963016, a lookalike of Sanofi's ($SNY) Lantus, has been accepted for review by the European Medicines Agency. LY2963016 is a new insulin glargine product and has been filed through the EMA's biosimilar pathway. Release

> Novartis ($NVS) and India's BioE are partnering on two new vaccines for typhoid and paratyphoid fevers. Story

> AstraZeneca ($AZN) will work with the Sarah Cannon Research Institute on new cancer drugs. Story

> BioDelivery Sciences International ($BDSI) has landed a $20 million loan. Release

> Astex Pharmaceuticals ($ASTX) says it will file an IND for ASTX727, an oral hypomethylating agent, in the fourth quarter of this year. Release

Medical Device News

 @FierceMedDev: Roche chases FDA cancer indication for HPV diagnostic. Story | Follow @FierceMedDev

 @MarkHFierce: Duke has found early promise with a blood Dx  that predicts aspirin treatment success. Report | Follow @MarkHFierce

 @DamianFierce: Patient lawsuits mount as India tries to crack down on unethical clinical trials. Item | Follow @DamianFierce

> Nikon mulls entry into medical devices business. Story

> Crescendo Bioscience achieves Medicare coverage for RA Dx. News

Pharma News

 @FiercePharma: Cost watchdogs veto Novartis breast cancer med Afinitor. NICE says "disappointed" data isn't stronger. News | Follow @FiercePharma

> Vivus, FMC both tout proxy advisers' support for board nominees. Article

> Medicare won't pay for Eli Lilly Alzheimer's agent. News

> Roche bids for broad use of HPV test to screen for cervical cancer. Story

> Cost watchdogs veto Novartis breast cancer med Afinitor. More

> Vivus, FMC both tout proxy advisers' support for board nominees. Article

CRO News

> Report: Academia could better use CROs for early research. News

> Lawsuits mount as India pushes trial reforms. Article

> CRO Blue Sky taps new CEO amid growth. Story

> Parexel teams with Rutgers for clinical trials. More

> CROs shift as early-phase demand dries up. News

Biotech IT News

> Report: Pharma execs warm to med reminder apps. News

> GE, Accenture back analytics provider in $20M financing. Article

> Bioinformatics gives U. Wisconsin team an 'edge' in cystic fibrosis study. Story

> AstraZeneca snaps up drug-discovery software from Cambridge startup. More

> Facebook, Twitter bolster Canadian biotech's research of Crohn's therapy. News

And Finally… A new study concludes that doctors who carefully individualize treatment for diabetes in patients over the age of 70 can achieve significantly better outcomes. Story

Suggested Articles

When it’s time to go public, most biotech companies for the Nasdaq. Not so for SQZ Biotech, which raised $71 million in its NYSE debut.

The saga of COVID antibody R&D continues as the REGN-COV2 antibody cocktail used by President Donald Trump has been hit by safety concerns.

A Dartmouth-led team proposed a method for targeting and inhibiting the most aggressive cells in breast tumors to improve responses to chemotherapy.